Inherent Targeting is developing nerve targeted fluorescent contrast agents to improve surgical outcomes. Nerve injury is a feared surgical complication affecting 50 million patients and incurring a $5 billion cost to the healthcare system annually. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. Our technology provides direct highlighting of nerves during surgery in real time and is currently under clinical translation. Since our recent spinout we have completed lead optimization and identified bright, water-soluble, and safe compounds for planned first in human clinical trials in 2022.